Icon
+91 94997 68112
Login Register

Qtern - (10 mg/5 mg; Tablet, Oral)

Dapagliflozin and Saxagliptan Astrazeneca
10 mg/5 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
 None
Qtern is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus
Yes
*** **** *** ***** * ******* **** ** ******. *** **** ***** * **** **, *** *** *** *********. ********* ** ******** ****** ** *** ****, ** *** ***** * **** *** ** ****** ******* (*** **, ****). **, ** **** ****** ******* ***** **** ****. *****://***.**********.***.***/**********_****/*********/****/********************.***
Qtern Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
*** **** **** *** **** *** **** *** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ***
*** ****** **** *** **** ** *** **, **** **** *** *** ********* *** ********* *** ********* *** ********* **** *** *** ********* **** *** **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ ** ** ** ********* ******** ** *** **, ****
*** ****** *** \ ********* ** ******* ********* ******** ****** *** **, ****
  1. *** *, **** : * **** ** ***** ** *** **** *** * ******* *********
  2. *** **, **** : *** ****** ******** *********** ***** ***** **** ** ****** ** ****** **. '***.
  3. *** *, **** : ******** *** *** ****** ******* ********** *** *** ****** ****** '*** ************.

Qtern - (5mg/5mg; Tablet)

Dapagliflozin and Saxagliptan Astrazeneca
5mg/5mg; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
Less Than 5
 None
Qtern is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus
Yes
* **** ** ***** ** ******* *******, *** *** ********* ***.
Qtern Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* ******* *** \ ********* ** ** **** *** ***** ** *******.
  1. *** **, **** : * **** ** ***** ** ******* *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.